Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of Ga-68-Tris (Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer

Michael S Hofman; Peter Eu; Price Jackson; Emily Hong; David Binns; Amir Iravani; Declan Murphy; Catherine Mitchell; Shankar Siva; Rodney J Hicks; Jennifer D Young; Philip J Blower; Gregory E Mullen

Journal article

Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of Ga-68-Tris (Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer

Michael S Hofman, Peter Eu, Price Jackson, Emily Hong, David Binns, Amir Iravani, Declan Murphy, Catherine Mitchell, Shankar Siva, Rodney J Hicks, Jennifer D Young, Philip J Blower, Gregory E Mullen

JOURNAL OF NUCLEAR MEDICINE | SOC NUCLEAR MEDICINE INC | Published : 2018

DOI: 10.2967/jnumed.117.199554

Abstract

68Ga-labeled urea-based inhibitors of the prostate-specific membrane antigen (PSMA), such as 68Ga-labeled N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid (HBED)-PSMA-11, are promising small molecules for targeting prostate cancer. A new radiopharmaceutical, 68Ga-labeled tris(hydroxypyridinone) (THP)-PSMA, has a simplified design for single-step kit-based radiolabeling. It features the THP ligand, which forms complexes with 68Ga3+ rapidly at a low concentration, at room temperature, and over a wide pH range, enabling direct elution from a 68Ge/68Ga generator into a lyophilized radiopharmaceutical kit in 1 step without manipulation. The aim of this phase 1 study was to assess the s..

View full abstract

University of Melbourne Researchers

Michael Hofman Author The Sir Peter Maccallum Department of Oncology

Declan Murphy Author Surgery - St Vincent's Hospital

Rodney Hicks Author The Sir Peter Maccallum Department of Oncology

Shankar Siva Author The Sir Peter Maccallum Department of Oncology

Grants

Awarded by Imperial College London EPSRC Centre for Doctoral Training in Medical Imaging

Awarded by Engineering and Physical Sciences Research Council

Funding Acknowledgements

The study received funding from Theragnostics Ltd. Philip J. Blower and Gregory E. Mullen are named inventors on patents whose claims encompass the THP chelator. Jennifer D. Young is funded by the King's College London and Imperial College London EPSRC Centre for Doctoral Training in Medical Imaging (EP/L015226/1). We acknowledge support from the KCL and UCL Comprehensive Cancer Imaging Centre funded by CRUK and EPSRC in association with the MRC and DoH (England) and support from the NIRH Biomedical Research Centre awarded to the Guy's and St. Thomas' NHS Foundation Trust in partnership with the King's College London and King's College Hospital NHS Foundation Trust. No other potential conflict of interest relevant to this article was reported.